Sort   by:  
 Page size 
ProteomicsMass spectrometry-based proteomics discovery of prognostic biomarkers in adrenal cortical carcinoma
Adrenal cortical carcinoma (ACC) is an extremely rare disease with a variable prognosis. Current prognostic markers have limitations in identifying patients with a poor prognosis. Herein, we aimed to investigate the prognostic protein biomarkers of ACC using mass-spectrometry-based proteomics. We pe...
ORGANISM(S): Homo sapiens (Human) 
2021-09-07 | PXD027404 | Pride
Human Ffpe Lfq Adrenal cortical carcinoma Biomarkers 
MetabolomicsFSCN1 as a new druggable target in adrenocortical carcinoma

Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with a high risk of relapse and metastatisation. The actin-bundling protein fascin (FSCN1) is overexpressed in aggressive ACC and represents a reliable prognostic indicator. FSCN1 has been shown to synergize with the Rho/Rac GEF VAV2 i...

2023-03-20 | MTBLS6402 | MetaboLights
TranscriptomicsAdrenocortical Carcinoma Gene Expression Profiling [Agilent]
Adrenocortical carcinoma (ACC) is an aggressive endocrine tumor with a poor 5 year survival rate of 10-20%. We used expression profiling to assess the transcriptional changes associated with ACC as compared to normal adrenal glands with the goal of identifying new targets for treatment. Fourteen A...
ORGANISM(S): Homo sapiens 
2013-11-21 | E-GEOD-19775 | biostudies-arrayexpress
ProteomicsEffects of FSCN1 inactivation on protein expression in human adrenocortical cancer cells
Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with a high risk of relapse and metastatisation. The actin-bundling protein fascin (FSCN1) is overexpressed in aggressive ACC and represents a reliable prognostic indicator. FSCN1 has been shown to synergize with the Rho/Rac GEF VAV2 in e...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2022-11-18 | MSV000090738 | MassIVE
TranscriptomicsAdrenocortical Carcinoma Gene Expression Profiling [Affymetrix]
Background: Adrenocortical carcinoma (ACC) is associated with poor survival rates. The objective of the study was to analyze ACC gene expression profiling data prognostic biomarkers and novel therapeutic targets. Methods: 44 ACC and 4 normal adrenal glands were profiled on Affymetrix U133 Plus 2 ex...
ORGANISM(S): Homo sapiens 
2013-11-21 | E-GEOD-19750 | biostudies-arrayexpress
TranscriptomicsAdrenocortical Carcinoma Gene Expression Profiling
This SuperSeries is composed of the SubSeries listed below. Refer to individual Series
ORGANISM(S): Homo sapiens 
2013-11-21 | E-GEOD-19776 | biostudies-arrayexpress
TranscriptomicsMicroarray study of human adrenal zona glomerulosa (ZG), zona fasciculata (ZF) and aldosterone-producing adenomas (APA)
Learn about the transcriptome profiling of zona glomerulosa (ZG), zona fasciculata (ZF) and aldosterone-producing adenomas (APA) in human adrenals 21 pairs of zona fasciculata (ZF) and zona glomerulosa (ZG), and 14 paired aldosterone-producing adenomas (APAs) from 14 Conn’s syndrome patients and 7 p...
ORGANISM(S): Homo sapiens 
2015-09-15 | E-GEOD-64957 | biostudies-arrayexpress
TranscriptomicsTranscription profiling by array of human adrenocortical tumors to identify molecular predictors of diagnosis and prognosis
A ""Cartes d'Identite des Tumeurs"" (CIT) project from the french Ligue Nationale Contre le Cancer (http://cit.ligue-cancer.net). 92 samples on Affymetrix HG-U133 Plus 2.0 GeneChips arrays for 92 patients with Adrenocortical Tumors (ACT). 4 normal adrenal samples from the same batch are also include...
ORGANISM(S): Homo sapiens 
2009-01-15 | E-TABM-311 | biostudies-arrayexpress
TranscriptomicsSF-1 and RNF31 knockdown and forskolin treatment
The human adrenocortical carcinoma cell line NCI-H295R treated with siRNA targeting SF-1 or RNF31 with luciferase-targeting siRNA as control. Combined with forskolin treatment.
ORGANISM(S): Homo sapiens 
2012-02-01 | E-MEXP-3259 | biostudies-arrayexpress
GenomicsPOG_patient_18843 - samples
Genome and transcriptome sequence data from an adrenal cortical carcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study
EGAD00001002049 | EGA
Sort   by:  
 Page size